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Abstract 
Imino-quinolyl ligands L1-L5 were synthesized by condensation reactions and 
obtained in good yields. Reactions of the ligands with either PdCl2 (cod) or K2 [PtCl4 ] 
gave the corresponding palladium(II) and platinum(II) complexes 1-10 also in good 
yields. All the compounds were characterized by elemental analysis, IR, 1 H and 1 3 C 
NMR spectroscopy. X-ray crystallography was used to confirm the structures of these 
compounds. Molecular structures of 3 and 5 showed that the ligands coordinate to 
the metal centre through the two nitrogen atoms, generating a distorted square 
planar geometry around the palladium atom.  The new complexes exhibited 
remarkable cytotoxic activities against MCF-7 and HT-29 cancer cell lines. 
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1.0 Introduction 
Transition metal complexes containing nitrogen-donor ligands continue to be the 
subject of intense biological evaluations as the search for less toxic and more 
selective anticancer drugs continues [1]. The subtlety with which the ligands control 
the reactivity of transition metal ions and the reciprocal effects that the metal ions 
have on the properties of ligands are some of the interesting dimensions being 
explored in the search for suitable ligands in metallo-drugs [2]. Existing examples 
are seen in the use of pyridine based platinum(II) complexes as mimics of cisplatin, 
because the pyridine ligand gives rise to square planar complexes which are 
structurally similar to cisplatin [3]. One important aspect relating to planar ligands is 
that their complexes reduce the rate of deactivation by thiol containing groups 
without interfering with DNA binding [3]. The use of chelating, bidentate ligands has 
also been viewed as important in preventing trans-labilization and undesired 
displacement of the ligands by sulphur and nitrogen donors in biomolecules [4].  
 
Recent research has shown that for a palladium drug to be developed, it should be 
stabilized by a chelate or a strongly coordinated, bulky monodentate nitrogen ligand 
and a suitable leaving group [5]. Reports have also demonstrated that varying the 
aniline functionality allows the design of compounds with a wide range of physical 
and chemical properties that may provide desired steric congestion around the 
coordinated metal atom [6]. The steric hindrance is favourable for this type of work 
because it prevents axial approach to the metal atom, therefore inhibiting the 
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formation of a five-coordinate intermediate that would otherwise lead to a ligand 
substitution. This phenomenon permits high selectivity in binding to DNA [6]. It is 
against this background that we report the synthesis and characterization of 
sterically congested palladium(II) and platinum(II) complexes derived from 
quinoline imine bearing substituted aniline moiety. The new complexes were 
investigated in vitro for their potential to exert cytotoxicity on MCF-7 and HT-29 
cancer cells and the results are herein discussed. 
 
2.0 Experimental 
2.1 Materials and methods 
All reactions were carried out under nitrogen atmosphere using a dual 
vacuum/nitrogen line and standard Schlenk techniques unless stated otherwise. 
Solvents were dried and purified by heating at reflux under nitrogen in the presence 
of a suitable drying agent. All the reagents and starting materials were purchased 
from Sigma-Aldrich and were used without any further purification. The 
palladium(II) precursor PdCl2 (cod) was prepared following literature method [7]. 
The 1 H NMR experiments were performed on a Varian XR200 MHz spectrometer. IR 
spectra in solution were recorded with a Perkin-Elmer Spectrum 100 Series FT-IR 
instrument using nujol mulls on NaCl plates. Elemental analysis was performed on 
Server 1112 Series Elemental Analyzer. X-ray diffraction data for the compound was 
collected on a Agilent SuperNova diffractometer using mirror-monochromated Mo-
K radiation (= 0.71073 Å). The crystal structures were solved by direct methods 
using SHELX [8] and refined by full-matrix least-squares methods based on F2 [8] 
using SHELX [8] and using the graphics program OLEX2 [9].  
 
2.2 Synthesis of the ligands 
2.2.1 2-phenyliminomethylquinoline (L1) 
To a solution of 2-quinolinecarboxaldehyde (0.3830 g, 2.44 mmol) in CH2 Cl2  (10 ml) 
was added aniline (0.2269 g, 2.44 mmol) dropwise. The reaction was stirred at room 
temperature for 10 hrs, and a crude product was obtained after evaporation of the 
solvent. The product was washed with water (10 ml) and the organic material 
extracted with CH2 Cl2  (2 x 10 ml), and dried over anhydrous magnesium sulphate. 
Reddish brown oil was obtained upon evaporation of the solvent. Yield: 0.5214 g 
(92%); IR (nujol cm-1 ); ν(C=N imine) 1626, ν(C=N quinolyl) 1598, ν(C=C quinolyl) 
1560, (C=C phenyl) 1503; 1 H NMR (200 MHz, CDCl3 ):  8.79 (s, 1H, quinolyl); 8.37 
(d, 1H, J = 8.4, quinolyl); 8.27 (dd, 1H, J = 8.2, quinolyl); 7.93 – 7.10 (m, 4H, 
quinolyl and imine); 6.79 – 6.66 (m, 5H, phenyl); 1 3 C NMR (50 MHz, CDCl3 )  
154.84, 115.07, 136.64, 129.92, 147.97, 127.72, 121.23, 128.90, 127.75, 160.89 (imine), 
150.81, 118.65, 129.71, 126.95, 129.25, 118.53; Anal. Calcd for C1 6 H1 2 N2 : C, 82.73; H, 
5.21; N, 12.06; Found: C, 82.95; H, 4.91; N, 12.32 
 
2.2.2 2-(2-methylphenyl)iminomethylquinoline (L2) 
The ligand was synthesized according to the procedure described for L1  using 2-
quinolinecarboxaldehyde (0.3266 g, 2.08 mmol) and 2-methylaniline (0.2227 g, 2.08 
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mmol). Reddish brown oil was obtained. Yield: 0.4713 g (92%); IR (nujol cm-1 ); 
ν(C=N imine) 1625, ν(C=N quinolyl) 1595, ν(C=C quinolyl) 1560, (C=C phenyl) 1504; 
1 H NMR (200 MHz, CDCl3 ):  8.68 (s, 1H, quinolyl); 8.38 (d, 1H, J = 8.8, quinolyl); 
8.19 (dd, 1H, J = 8.4, quinolyl); 7.88 – 6.98 (m, 4H, quinolyl and imine); 6.72 – 6.63 
(m, 5H, phenyl); 2.42 (s, 3H, Me); 1 3 C NMR (50 MHz, CDCl3 )  155.08, 114.89, 
136.58, 132.59, 147.93, 127.65, 126.63, 128.88, 127.74, 160.01 (imine), 149.81, 118.65, 
130.43, 126.92, 129.88, 117.48, 17.88; Anal. Calcd for C1 7 H1 4 N2 : C, 82.90; H, 5.73; N, 
11.37; Found: C, 83.14; H, 6.02; N, 11.55 
 
2.2.3 2-(2,6-dimethylphenyl)iminomethylquinoline (L3) 
The ligand was synthesized according to the procedure described for L1  using 2-
quinolinecarboxaldehyde (0.2913 g, 1.85 mmol) and 2,6-dimethylaniline (0.2246 g, 
1.85 mmol). Reddish brown oil was obtained. Yield: 0.4527 g (94%); IR (nujol cm-1 ); 
ν(C=N imine) 1639, ν(C=N quinolyl) 1595, ν(C=C quinolyl) 1562, (C=C phenyl) 1503; 
1 H NMR (200 MHz, CDCl3 ):  8.50 (s, 1H, quinolyl); 8.42 (d, 1H, J = 8.4, quinolyl); 
8.22 (dd, 1H, J = 8.0, quinolyl); 7.91 – 6.92 (m, 4H, quinolyl and imine); 6.67 – 6.63 
(m, 5H, phenyl); 2.19 (s, 6H, Me); 13C NMR (50 MHz, CDCl3 )  154.62, 117.99, 136.71, 
129.95, 145.53, 127.78, 124.15, 128.22, 128.14, 163.84 (imine), 150.30, 121.68, 129.77, 
126.79, 129.05, 118.18, 18.31, 17.59; Anal. Calcd for C1 8H1 6 N2 : C, 83.04; H, 6.19; N, 
10.76; Found: C, 83.27; H, 6.45; N, 11.01  
   
2.2.4 2-(2,6-diethylphenyl)iminomethylquinoline (L4) 
The ligand was synthesized according to the procedure described for L1  using 2-
quinolinecarboxaldehyde (0.3130 g, 1.99 mmol) and 2,6-diethylaniline (0.2972 g, 
1.99 mmol). Reddish brown oil was obtained [10]. Yield: 0.5509 g (96%); IR (nujol 
cm-1 ); ν(C=N imine) 1641, ν(C=N quinolyl) 1596, ν(C=C quinolyl) 1563, (C=C phenyl) 
1504; 1 H NMR (200 MHz, CDCl3 ):  8.47 (s, 1H, quinolyl); 8.39 (d, 1H, J = 8.4, 
quinolyl); 8.21 (dd, 1H, J = 8.4, quinolyl); 7.91 – 6.94 (m, 4H, quinolyl and imine); 
6.76 – 6.69 (m, 5H, phenyl); 2.52 (dd, 4H, Me); 1.57 – 1.09 (m, 6H, Me); 1 3 C NMR 
(50 MHz, CDCl3 )  154.55, 118.16, 136.70, 132.62, 147.92, 127.73, 125.96, 129.02, 
127.73, 163.43 (imine), 149.54, 124.32, 129.89, 126.25, 129.76, 118.26, 24.65, 24.23, 
14.53, 12.97; Anal. Calcd for C2 0H2 0N2 : C, 83.30; H, 6.99; N, 9.71; Found: C, 83.54; 
H, 6.78; N, 9.99 
 
2.2.5 2- (2,6-diisopropylphenyl) iminomethylquinoline (L5) 
The ligand was synthesized according to the procedure described for L1  using 2-
quinolinecarboxaldehyde (0.3318 g, 2.11 mmol) and 2,6-diisopropylaniline (0.3743 g, 
2.11 mmol). Reddish brown oil was obtained. Yield: 0.6276 g (94%); IR (nujol cm-1 ); 
ν(C=N imine) 1642, ν(C=N quinolyl) 1595, ν(C=C quinolyl) 1562, (C=C phenyl) 1504; 
1 H NMR (200 MHz, CDCl3 ):  8.45 (s, 1H, quinolyl); 8.40 (d, 1H, J = 8.2, quinolyl); 
8.21 (dd, 1H, J = 8.0, quinolyl); 7.91 – 7.04 (m, 4H, quinolyl and imine); 6.79 – 6.68 
(m, 5H, phenyl); 3.05 – 2.87 (m, 2H, Me); 1.22 (dd, 12H, J = 1.2, Me); 1 3 C NMR (50 
MHz, CDCl3 )  154.57, 118.33,  136.78, 132.48, 148.03, 124.56, 129.86, 129.11, 163.44 
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(imine), 148.44, 127.81, 129.98,  23.08, 28.02, 23.44, 22.47; Anal. Calcd for 
C2 2 H2 4 N2 : C, 83.50; H, 7.64; N, 8.85; Found: C, 83.25; H, 7.92; N, 8.59 
 
2.3 Synthesis of palladium(II) complexes 
2.3.1 Dichloro-[2-(phenyliminomethyl)quinoline]palladium(II) (1) 
To a solution of L1  (0.0748 g, 0.322 mmol) in dry CH2 Cl2  (10 ml) was added 
dropwise a solution of PdCl2 (cod) (0.0925 g, 0.324 mmol) in CH2 Cl2  (5 ml). The 
yellow solution was refluxed for 4 hrs, resulting in the formation of yellow 
precipitate. The precipitate was filtered and washed with Et2 O (2 x 10 ml) to obtain a 
pure yellow solid which formed single crystals suitable for X-ray crystallography 
when it was recrystallized from a mixture of CH2 Cl2 :C6H14 solution [11]. Yield: 0.1082 
g (82%); IR (nujol cm-1 ); ν(C=N imine) 1599, ν(C=N quinolyl) 1588, ν(C=C quinolyl) 
1572, (C=C phenyl) 1511; 1 H NMR (200 MHz, DMSO):  8.50 (d, 1H, J = 8.4, 
quinolyl); 8.30 (d, 1H, J = 8.2, quinolyl); 8.11 – 7.28 (m, 4H, quinolyl and imine); 
8.77 (d, 1H, J = 8.0, quinolyl); 6.87 – 6.70 (m, 5H, phenyl); Anal. Calcd for 
C1 6 H1 2 Cl2 N2 Pd: C, 46.92; H, 2.95; N, 6.84; Found: C, 47.20; H, 3.11; N, 6.99 
 
2.3.2 Dichloro-[2-(2-methylphenyl)iminomethylquinoline]palladium(II) (2) 
The compound was synthesized according to the procedure described for 1  using L2 
(0.0634 g, 0.257 mmol) and PdCl2 (cod) (0.0744 g, 0.257 mmol). A yellow solid was 
obtained. Yield: 0.0969 g (89%); IR (nujol cm-1 ); ν(C=N imine) 1599, ν(C=N 
quinolyl) 1589, ν(C=C quinolyl) 1561, (C=C phenyl) 1500; 1 H NMR (200 MHz, 
DMSO):  8.46 (d, 1H, J = 8.2, quinolyl); 8.36 (d, 1H, J = 8.2, quinolyl); 8.16 – 7.04 
(m, 4H, quinolyl and imine); 8.76 (d, 1H, J = 8.8, quinolyl); 6.85 – 6.68 (m, 5H, 
phenyl); Anal. Calcd for C1 7 H1 4 Cl2 N2 Pd: C, 48.20; H, 3.33; N, 6.61; Found: C, 48.48; 
H, 3.17; N, 6.52 
 
2.3.3 Dichloro-[2-(2,6-dimethylphenyl)iminomethylquinoline]palladium(II) (3) 
The compound was synthesized according to the procedure described for 1  using L3 
(0.0557 g, 0.214 mmol) and PdCl2 (cod) (0.0623 g, 0.218 mmol). A yellow solid was 
obtained. Suitable crystals for X-ray crystallography were grown by slow evaporation 
of CH3 CN solution of the complex. Yield: 0.0805 g (86%) IR (nujol cm-1 ); ν(C=N 
imine) 1599, ν(C=N quinolyl) 1585, ν(C=C quinolyl) 1565, (C=C phenyl) 1510; 1 H 
NMR (200 MHz, DMSO):  8.42 (d, 1H, J = 8.2, quinolyl); 8.34 (d, 1H, J = 8.2, 
quinolyl); 8.27 – 6.96 (m, 4H, quinolyl and imine); 8.72 (d, 1H, J = 7.8, quinolyl); 
6.82 – 6.73 (m, 5H, phenyl); Anal. Calcd for C1 8H1 6 Cl2 N2 Pd: C, 49.40; H, 3.68; N, 
6.40; Found: C, 49.16; H, 3.88; N, 6.22 
 
2.3.4  Dichloro-[2-(2,6-diethylphenyl)iminomethylquinoline]palladium(II) (4) 
The compound was synthesized according to the procedure described for 1  using L4 
(0.0640 g, 0.222 mmol) and PdCl2 (cod) (0.0650 g, 0.228 mmol). A yellow solid was 
obtained. Suitable crystals for X-ray crystallography were grown by slow evaporation 
of CH3 CN solution of the complex [10]. Yield: 0.0848 g (82%) IR (nujol cm-1 ); ν(C=N 
imine) 1602, ν(C=N quinolyl) 1584, ν(C=C quinolyl) 1563, (C=C phenyl) 1506; 1 H 
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NMR (200 MHz, DMSO):  8.42 (d, 1H, J = 8.4, quinolyl); 8.36 (d, 1H, J = 8.2, 
quinolyl); 8.23 – 6.96 (m, 4H, quinolyl and imine); 8.77 (d, 1H, J = 7.4, quinolyl); 
6.88 – 6.78 (m, 5H, phenyl); Anal. Calcd for C2 0H2 0Cl2 N2 Pd: C, 51.58; H, 4.33; N, 
6.02; Found: C, 51.89; H, 4.18; N, 5.83 
 
2.3.5 Dichloro-[2-(2,6-diisopropylphenyl)iminomethylquinoline]palladium(II) (5) 
The compound was synthesized according to the procedure described for 1  using L5 
(0.0645 g, 0.204 mmol) and PdCl2 (cod) (0.0598, 0.209 mmol). A yellow solid was 
obtained. Suitable crystals for X-ray crystallography were grown by slow diffusion of 
C6 H1 4  into a solution of the complex in CH2 Cl2 .Yield: 0.0856 g (85%) IR (nujol cm-1 ); 
ν(C=N imine) 1606, ν(C=N quinolyl) 1589, ν(C=C quinolyl) 1562, (C=C phenyl) 1514;   
1 H NMR (200 MHz, DMSO):  8.44 (d, 1H, J = 8.4, quinolyl); 8.35 (d, 1H, J = 8.0, 
quinolyl); 8.22 – 6.98 (m, 4H, quinolyl and imine); 8.78 (d, 1H, J = 7.6, quinolyl); 
6.78 – 6.71 (m, 5H, phenyl); Anal. Calcd for C2 2 H2 4 Cl2 N2 Pd: C, 53.51; H, 4.90; N, 
5.67; Found: C, 53.28; H, 4.72; N, 5.93 
 
2.4 Synthesis of platinum(II) complexes 
2.4.1 Dichloro-[2-(phenyliminomethyl)quinoline]platinum(II) (6) 
To a solution of L1  (0.0627 g, 0.270 mmol) in dry MeOH (10 ml) was added 
dropwise an aqueous solution of K2 [PtCl4 ] (0.1115 g, 0.269 mmol) (5 ml). The 
reaction was stirred at room temperature for 15 hrs, resulting in the formation of an 
orange precipitate. The precipitate was filtered and washed with Et2 O (2 x 10 ml) to 
obtain a pure orange solid. Yield: 0.1019 g (76%); IR (nujol cm-1 ) ν(C=N imine) 1610, 
ν(C=N quinolyl) 1586, ν(C=C quinolyl) 1560, (C=C phenyl) 1510;  1 H NMR (200 MHz, 
DMSO):  8.62 (d, 1H, J = 9.2, quinolyl ); 8.33 (d, 1H, J = 8.8, quinolyl); 8.12 – 7.03 
(m, 4H, quinolyl and imine); 8.71 (d, 1H, J = 8.4, quinolyl); 6.89 – 6.59 (m, 5H, 
phenyl); Anal. Calcd for C1 6 H1 2 Cl2 N2 Pt: C, 38.57; H, 2.43; N, 5.62; Found: C, 38.72; 
H, 2.62; N, 5.76 
 
2.4.2 Dichloro-[2-(2-methylphenyl)iminomethylquinoline]platinum(II) (7) 
The compound was synthesized according to the procedure described for 6 using L2 
(0.0679 g, 0.276 mmol) and K2 [PtCl4 ] (0.1146 g, 0.276 mmol). An orange solid was 
obtained. Yield: 0.1060 g (75%); IR (nujol cm-1 ) ν(C=N imine) 1612, ν(C=N quinolyl) 
1588, ν(C=C quinolyl) 1557, (C=C phenyl) 1512; 1 H NMR (200 MHz, DMSO):  8.57 
(d, 1H, J = 8.6, quinolyl); 8.34 (d, 1H, J = 8.0, quinolyl); 8.25 – 7.17 (m, 4H, quinolyl 
and imine); 8.72 (d, 1H, J = 8.4, quinolyl); 6.79 – 6.58 (m, 5H, phenyl); Anal. Calcd 
for C1 7 H1 4 Cl2 N2 Pt: C, 39.86; H, 2.75; N, 5.47; Found: C, 40.08; H, 3.03; N, 5.33 
 
2.4.3 Dichloro-[2-(2,6-dimethylphenyl)iminomethylquinoline]platinum(II) (8) 
The compound was synthesized according to the procedure described for 6 using L3 
(0.0643 g, 0.247 mmol) and K2 [PtCl4 ] (0.1035 g, 0.249 mmol). An orange solid was 
obtained. Yield: 0.1014 g (78%); IR (nujol cm-1 ) ν(C=N imine) 1607, ν(C=N quinolyl) 
1589, ν(C=C quinolyl) 1561, (C=C phenyl) 1513; 1 H NMR (200 MHz, DMSO):  8.44 
(d, 1H, J = 8.0, quinolyl); 8.32 (d, 1H, J = 8.6, quinolyl); 8.01 – 6.92 (m, 4H, quinolyl 
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and imine); 8.73 (d, 1H, J = 8.4, quinolyl); 6.78 – 6.59 (m, 5H, phenyl); Anal. Calcd 
for C1 8H1 6 Cl2 N2 Pt: C, 41.08; H, 3.06; N, 5.32; Found: C, 40.94; H, 2.77; N, 5.06 
 
2.4.4 Dichloro-[2-(2,6-diethylphenyl)iminomethylquinoline]platinum(II) (9) 
The compound was synthesized according to the procedure described for 6 using L4 
(0.0728 g, 0.252 mmol) and K2 [PtCl4 ] (0.1059 g, 0.255 mmol). An orange solid was 
obtained. Yield: 0.1034 g (74%); IR (nujol cm-1 ) ν(C=N imine) 1608, ν(C=N quinolyl) 
1587, ν(C=C quinolyl) 1566, (C=C phenyl) 1516; 1 H NMR (200 MHz, DMSO):  8.43 
(d, 1H, J = 8.6, quinolyl); 8.35 (d, 1H, J = 8.2, quinolyl); 8.19 – 6.89 (m, 4H, quinolyl 
and imine); 8.72 (d, 1H, J = 8.2, quinolyl); 6.76 – 6.56 (m, 5H, phenyl); Anal. Calcd 
for C2 0H2 0Cl2 N2 Pt: C, 43.33; H, 3.64; N, 5.05; Found: C, 43.09; H, 3.91; N, 5.22 
 
2.4.5 Dichloro-[2-(2,6-diisopropylphenyl)iminomethylquinoline]platinum(II) (10) 
The compound was synthesized according to the procedure described for 6 using L5 
(0.0472 g, 0.149 mmol) and K2 [PtCl4 ] (0.0633 g, 0.152 mmol). An orange solid was 
obtained. Yield: 0.0651 g (75%); IR (nujol cm-1 ) ν(C=N imine) 1612, ν(C=N quinolyl) 
1588, ν(C=C quinolyl) 1564, (C=C phenyl) 1514; 1 H NMR (200 MHz, DMSO):  8.42 
(d, 1H, J = 8.0, quinolyl); 8.37 (d, 1H, J = 8.4, quinolyl); 8.12 – 6.85 (m, 4H, quinolyl 
and imine); 8.75 (d, 1H, J = 8.6, quinolyl); 6.64 – 6.48 (m, 5H, phenyl); Anal. Calcd 
for C2 2 H2 4 Cl2 N2 Pt: C, 45.37; H, 4.15; N, 4.81; Found: C, 45.13; H, 4.35; N, 5.02 
 
2.5 Cytotoxicity determination 
2.5.1 Cell culture 
The A2780 and MCF-7 cells were cultured in RPMI-1640 in 25cm tissue culture 
flasks and were allowed to grow to 90% confluency in an incubator set at 37 ºC 
containing 5% CO2  atmospheric pressure, before they were trypsinized and cultured 
in 6 tissue culture plates. Stock and final concentrations of the complexes were 
prepared in the culture media. 
 
2.5.2 MTT assay 
The cells were plated in 96-well tissue plates at a density of 2.0 x 105  cells per well 
and treated with various concentrations of the palladium complexes that ranged 
from 100 to 10µM after which they were incubated for 24 hrs. Triplicate wells were 
established for each concentration. Just 5 hrs before the elapse of 24 hours, 10µl of 
5mg/ml MTT solution was added to each well and the plates were further incubated. 
At the end of the incubation period, the media was removed from each well and 
replaced with 50 µl of DMSO. The plates were shaken on a rotating shaker for 10 
minutes before taking readings at 560 nm using a microplate reader. 
 
3.0 Results and discussion 
3.1 Synthesis of the ligands and metal complexes 
Imino-quinolyl ligands L1-L5 were successfully prepared by reacting 2-
quinolinecarboxaldehyde with substituted aniline and obtained in very good yields. 
Ligand L4 has been previously reported by our group, but it was not fully 
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characterized [10]. The rest of the ligands have been reported by another research 
group [12] but they were independently prepared by us. The new corresponding 
palladium(II) and platinum(II) complexes 1-10 were subsequently prepared by 
equimolar reactions of the ligands with either PdCl2 (cod) or K2 [PtCl4 ] (Scheme 1). All 
the compounds were characterized using elemental analysis, IR, 1 H and 1 3 C NMR 
spectroscopy. 
                              
N
N
PdCl2(cod)
K2[PtCl4]
M
Cl Cl
O N
NH2
R1
R2
+
CH2Cl2
rt, 10 h
N
N
R1
R2
R1
R2
 
R1  = R2  = H, M = Pd (1); M = Pt (6) 
R1  = Me, R2  = H, M = Pd (2); M = Pt (7) 
R1  = R2  = Me, M = Pd (3); M = Pt (8) 
R1  = R2  = Et, M = Pd (4); M = Pt (9) 
R1  = R2  = iPr, M = Pd (5); M = Pt (10) 
 
Scheme 1 
 
The micro-analysis data are consistent with the proposed molecular formulae. The IR 
spectra of the ligands showed three strong absorption bands between 1625 and 1647 
cm-1 , which confirmed imine formation [13-15]. The other strong bands observed 
around 1595 cm-1  and 1559 cm-1  show the presence of (C=N) and (C=C) quinolyl 
vibrations respectively. Coordination of the ligands to the metal centre was 
confirmed by lower absorption frequencies between 1618 and 1599 cm-1  compared to 
their corresponding free ligands [13-15]. The (C=N) and (C=C) quinolyl vibrations 
did not show any significant shift in absorption frequency from their corresponding 
free imines, confirming their non involvement in coordination.  
 
8 
 
In the 1 H NMR spectra of the ligands, the signal for the imine proton was obscured 
by the aromatic signals. The quinolyl protons appeared as doublets or triplets 
between 8.79 and 8.13 ppm due to vicinal proton-proton coupling. In the 1 3 C NMR 
analysis, the characteristic signals for the imine carbons appeared at around 163.00 
ppm [13-15]. In the NMR spectra of the complexes, the signals generally shifted 
downfield with respect to their position in the free ligand due to coordination of the 
ligand. 
 
3.2 Single crystal X-ray diffraction studies 
The molecular structures of some of the complexes were confirmed by X-ray 
crystallography.  Crystallographic data and refinement parameters are summarized 
in Table 1, while selected bond lengths and bond angles are summarized in Table 2. 
The molecular structures are shown in Fig. 1 and 2 respectively. 
 
Fig. 1. X-ray crystal structure of complex 3. 
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Fig. 2. X-ray crystal structure of complex 5. 
 
Table 1: Crystallographic data and refinement for complexes 3 and 5 
Crystallographic data                  3               5 
 
Empirical formula 
Formula weight 
Temperature (K) 
Crystal system  
Space group 
Unit cell dimensions 
a (Å) 
b (Å) 
c (Å) 
β (°) 
V (Å3 ) 
Z 
Dca l (Mgm-3 ) 
F(000) 
Absorption coefficient (mm-
1 )  
Crystal size (mm3 ) 
Number of data collected 
Number of parameters 
refined 
R[(F2 >2σ(F2)] 
wR(F2) 
Theta range for data 
collection 
Goodness-of-fit on F2  
Largest diff. peak and hole 
2(C1 8H1 6 Cl2 N2 Pd).C2 H3
N 
916.31 
100 
triclinic 
P-1 
 
8.0349(5) 
13.5623(8) 
17.5006(10) 
77.043(5) 
1831.70(19) 
2 
1.661 
916 
1.31 
0.3 x 0.3 x 0.3 
7435 
447 
0.036 
0.091 
2.8 to 26.4° 
1.08 
0.67 and -1.08 e.Å-3  
C2 2 H2 4 Cl2 N2 Pd 
492.72 
100 
monoclinic 
P21/c 
 
11.4731(6) 
13.0007(8) 
14.8263(8) 
106.356(6) 
2122.0(2) 
4 
1.542 
1000 
1.14 
0.3 x 0.2 x 0.2 
4344 
248 
0.043 
0.089 
2.9 to 26.3° 
1.09 
0.81 and -0.82 e.Å-3  
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Table 2: Selected bond lengths and bond angles for compounds 3 and 5               
Compound           Bond length (Å)                   Bond angle (◦) 
 
     3 
 
 
Pd(1)–N(2)             2.020(2)                      
Pd(1)–N(1)             2.074(3)                
Pd(1)–Cl(2)            
2.2788(9)                 
Pd(1)–Cl(1)            2.2941(8) 
 
Pd(2)–N(3)             2.014(3)                      
Pd(2)–N(4)             2.110(3)                
Pd(2)–Cl(3)            
2.2736(8)                 
Pd(2)–Cl(4)            
2.2956(9) 
 
N(2)–Pd(1)–N(1)                
80.32(11)                        
Cl(2)–Pd(1)–Cl(1)            
88.75(3)                          
N(1)–Pd(1)–Cl(1)             98.36(7)                      
N(2)–Pd(1)–Cl(2)             
91.94(8)
 
N(4)–Pd(2)–N(3)                
80.23(11)                        
Cl(4)–Pd(2)–Cl(3)            
87.53(3)                          
N(3)–Pd(2)–Cl(3)             
90.81(8)                      
N(4)–Pd(2)–Cl(4)              
101.50(8) 
 
     5 
 
 
 
 
Pd(1)–N(4)            2.026(3)                      
Pd(1)–N(2)            2.098(3)                
Pd(1)–Cl(3)             
2.2769(10)                 
Pd(1)–Cl(2)            
2.3081(10) 
 
N(4)–Pd(1)–N(2)                
80.45(12)                        
Cl(3)–Pd(1)–Cl(2)              
88.13(14)                          
N(2)–Pd(1)–Cl(2)             
99.99(9)                      
N(4)–Pd(1)–Cl(3)             
92.69(9) 
 
 
 
Complex 3 crystallizes in the triclinic space group P-1, with two structurally identical 
molecules (A and B) in the asymmetric unit (rms deviation of 0.173 Å when fitting 
inverted molecule B on molecule A), while 5 crystallizes in the monoclinic space 
group P21/c. In the structures, π-π interactions between quinoline rings link two 
molecules into centro-symmetric dimers. The palladium atom is four coordinated by 
two chloride anions and two nitrogen atoms of the bidentate ligand, generating a 
distorted square planar coordination geometry around the palladium metal centre. 
The bond angles around the palladium metal atom of N(2)–Pd(1)–N(1) and Cl(2)–
Pd(1)–Cl(1): 80.32(11)° and 88.75(3)° for molecule A in 3 and 80.45(12)° and 
88.13(14)° in 5 showed significant deviations from 90°, which confirms the 
distortion in the square planar geometry. These bond angles are in agreement with 
those of closely related compounds [11,13,14]. The Pd(1)–C1(1) and Pd(1)–C1(2) bond 
lengths of 2.2941(8)Å and 2.2788(9)Å for molecule A in 3 and 2.2769(10)Å and 
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2.3081(10)Å in 5 are in good agreement with the average Pd–Cl bond distance of 
2.298(15)Å for known palladium complexes [16,17]. There is detectable trans- 
influence taking place for the chloride ligands since the bond distance Pd(1)–Cl(1) is 
slightly longer than Pd(1)–Cl(2), thus reflecting the stronger trans- influence of the 
quinolyl group compared to the secondary amine [18]. 
 
3.3 Cytotoxicity studies 
The aim of this study was to evaluate imino-quinolyl palladium(II) and platinum(II) 
complexes as possible antitumor agents. The complexes were derived from chelating, 
bidentate quinolyl imine ligands containing substituted aniline, thereby making 
them sterically congested. As indicated earlier, steric congestion protects the central 
metal atom from deactivation, thereby permitting high selectivity to DNA binding 
[6], while chelating, bidentate ligands prevent trans-labilization and undesired 
displacement of the ligands [4]. 
 
The free imino-quinolyl ligand L1  and some palladium(II) complexes and 
platinum(II) complexes were evaluated for their potential to exert cytotoxicity on 
highly invasive human breast (MCF-7) and human colon (HT-29) tumor cells using 
3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay with 
minor modifications [19-21]. The compounds were first solubilized in 
dimethylsulfoxide (DMSO). Cell growth inhibition results, expressed as 
concentration of the complex required to inhibit tumor cell growth by 50% (IC5 0) are 
summarized in Table 3. Cytotoxicity of cisplatin was evaluated under the same 
experimental conditions for comparison. The imino-quinolyl ligand L1  was also 
evaluated to assess whether free imino-quinolyl ligands could exert cytotoxicity on 
cancer cells. However, the ligand did not return any appreciable activity (IC5 0  >100 
µM). The imino-quinolyl palladium(II) and platinum(II) complexes exhibited growth 
inhibitory activities against MCF-7 and HT-29 cancer cell lines which were superior 
to the reference compound cisplatin, which returned IC50 values around 100 µM. The 
highest cytotoxic activities were pronounced in complexes 5 and 10 (IC5 0  46.01 and 
39.90 µM), which were approximately two times more active than cisplatin against 
the two examined cancer cell lines. These complexes contain two iso-propyl groups 
substituted at ortho-positions on the phenyl ring, making them more sterically 
demanding. The trend confirms the importance of steric congestion in preventing 
axial approach to the coordinated metal atom and permitting high selectivity to DNA 
binding [6]. However, there was insignificant difference in activities between 
complexes containing two iso-propyl groups and those with two methyl groups on 
the phenyl ring. 
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Table 3: Cytotoxic activities for the free ligand and complexes tested against  
   MCF-7 and HT-29 cancer cell lines 
 
                                           IC50 (µM) 
      Compound        MCF-7         HT-29  
          L1         >100         >100 
Palladium(II) 
complexes 
          1 
          2 
          3 
          5       
 
         63.87 ± 0.23 
         62.76 ± 2.36 
         47.58 ± 1.66 
         46.01 ± 0.95 
 
          58.96 ± 2.98 
          57.88 ± 1.85 
          43.89 ± 0.74 
          42.79 ± 1.69 
Platinum(II) 
complexes 
          6 
          7 
          8 
          10 
 
         59.86 ± 2.38 
         57.59 ± 2.45 
         45.99 ± 0.99 
         44.90 ± 1.86 
 
          54.75 ± 0.81 
          53.84 ± 2.11 
          41.92 ± 1.33 
          39.90 ± 0.92 
        Cisplatin          100           100 
IC50 is the concentration of the complex required to inhibit cell growth by 50%  
Data are presented otherwise specified as mean ± SD of IC50 (µg/ml) from 3  
independent experiments 
 
All the complexes generally exhibited higher cytotoxic activities against human colon 
(HT-29) cell line (IC5 0  39.90-58.96 µM) compared to the human breast (MCF-7) cell 
line. Furthermore, imino-quinolyl platinum(II) complexes showed slightly superior 
cytotoxic activities compared to their palladium(II) counterparts across the 
examined cancer cell lines, probably due to the higher lability of palladium(II) 
compared to their platinum(II) analogues, which makes them to dissociate readily in 
solution, leading to very reactive species that are unable to reach their 
pharmacological targets [22-23]. The complexes are also square planar with metal 
chloride bonds in cis-position, and when considering the proposed mechanism of 
action of cisplatin [24,25], it is reasonable to suggest that cytotoxicity of these imino-
quinolyl complexes is derived from DNA binding. Our group has recently reported 
cytotoxic activities of complex 4 showing similar trend [10]. 
 
4.0 Conclusions 
We have successfully synthesized and fully characterized sterically congested 
palladium(II) and platinum(II) complexes derived from chelating imino-quinolyl 
ligands. The complexes were evaluated in vitro for their potential to exert 
cytotoxicity on human breast (MCF-7) and human colon (HT-29) cancer cell lines. 
The free ligand did not return any appreciable activity. However, the complexes 
exhibited growth inhibitory activities that were even better than cisplatin. 
 
13 
 
Acknowledgements 
The authors thank University of the Western Cape, National Research Foundation 
and University of Leuven’s International Admissions and Mobility Office (WMM) for 
financial support. The authors also thank the Hercules Foundation for supporting 
the purchase of the diffractometer through project AKUL/09/0035. 
 
Supplementary material 
CCDC no.  908050 and 908051 contain the supplementary crystallographic data for 
compound 3 and 5 respectively. Copies of this information may be obtained free of 
charge from The Director, CCDC, 12 Union Road, Cambridge, CB2 1EZ, UK (fax: 
+44-1223-336033; e-mail: deposit@ccdc.cam.ac.uk or www: 
http://www.ccdc.cam.ac.uk). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
14 
 
References 
[1] a) A.S. Abu-Surrah, K.A. Abu Safieh, I.M. Ahmad, M.Y.Abdalla, M.T. Ayoub, A.K.  
     Qaroush, A.M. Abu-Mahtheieh, Eur. J. Med. Chem. 45 (2010) 471  
b) E. Budzisz, M. Miernicka, I.P. Lorenz, P. Mayer, U. Krajewska, M. Rozalski,  
     Polyhedron. 28 (2009) 637 
c) F.K. Keter, S.O. Ojwach, O.A. Oyetunji, I.A. Guzei, J. Darkwa, Inorg. Chim. Acta  
     362 (2009) 2595  
d) M. Miernicka, A. Szulawska, M. Czyz, I.P. Lorenz, P. Mayer, B. Karwowski, E.  
     Budzisz, J. Inorg. Biochem. 102 (2008) 157  
e) F.K. Keter, S. Kanyanda, S.S.L. Lantagaye, J. Darwa, D.J.G. Rees, M. Meyer,     
     Cancer Chemother. Pharmacol. 63 (2008) 127 
[2] S.H. van Rijt, P.J. Sadler, Drug. Discov. Today. 14 (2009) 1089  
[3] a) M. van Beusichem, N. Farrell, Inorg. Chem. 31 (1992) 634 
b) J. Holford, F. Raynaud, B.A. Murrer, K. Grimaldi, J.A. Hartley, M. Abrams, L.R. 
     Kelland, Anti-Cancer Drug Des. 13 (1998) 1  
c) P. Kopf-Maier, H. Kopf, Chem. Rev. 87 (1987) 1137 
d) M.J. Clarke, F. Zhu, D.R. Frasca, Chem. Rev. 99 (1999) 2511  
[4] E. Wong, M. Giandomenico, Chem. Rev. 99 (1999) 2451  
[5] A.S. Abu-Surrah, H.H. Al-Sadoni, M.Y. Abdalla, Cancer Therapy. 6 (2008) 1  
[6] a) A.C.G. Hotze, Y. Chen, T.W. Hambley, S. Parsons, N.A. Kratochwil, J.A.  
     Parkison,.P. Munk, P.J. Sadler, Eur. J. Inorg. Chem. (2002) 1035 
b) M.L. Conrad, J.E. Enman, S.J. Scales, H. Zhang, C.M. Vogels, M.T. Saleh, A.  
     Decken, S.A. Westcott, Inorg. Chim. Acta. 358 (2005) 63  
c) S.J. Scales, H. Zhang, P.A. Chapman, C.P. McRory, E.J. Derah, C.M. Vogels, M.T.    
     Saleh, A. Decken, S.A. Westcott, Polyhedron. 23 (2004) 2169  
[7] J. Wiedermann, K. Mereiter, K. Kirchner, J. Mol. Catal. A: Chem. 257 (2006) 67  
[8] G. M. Sheldrick, Acta Cryst. A64 (2008) 112 
[9] O.V. Dolomanov, L.J. Bourhis, R.J. Gildea, J.A.K. Howard, H. Puschmann, J.  
      Appl. Cryst. 42 (2009) 339 
[10] W.M. Motswainyana, M.O. Onani, J. Jacobs, L. van Meervelt, Acta Cryst. C68 
(2012) m356  
[11] W.M. Motswainyana, M.O. Onani, A.M. Madiehe, Acta Cryst. E68 (2012) m380  
[12] A. Koppl, H.G. Alt, J. Mol. Catal. A: Chem. 154 (2000) 45 
[13] a) W.M. Motswainyana, M.O. Onani, A.M. Madiehe, Polyhedron. 41 (2012) 44  
b) W.M. Motswainyana, S.O. Ojwach, M.O. Onani, E.I. Iwuoha, J. Darkwa,      
     Polyhedron. 30 (2011) 2574 
[14] W. Zhang, W-H. Sun, B. Wu, S. Zhang, H. Ma, Y. Li, J. Cheng, P. Hao, J.  
        Organomet. Chem. 691 (2006) 4759 
[15] J.D.A. Pelletier, J. Fawcett, K. Singh, G.A. Solan, J. Organomet. Chem. 693  
        (2008) 2723  
[16] W. Chen, C. Xi, Y. Wu, J. Organomet. Chem. 692 (2007) 4381  
[17] F.H. Allen, Acta Crystallogr. B58 (2002) 380  
[18] S. Doherty, J.G. Knight, T.H. Scanlam, M.R.J. Elsegood, W Clegg, J. Organomet.  
            Chem. 650 (2002) 231  
15 
 
[19] Z. Petrovski, M.R.P. Norton de Matos, S.S. Braga, C.C.L. Pereira, M.L. Matos,  
    I.S. Goncalves, M. Pillinger, P.M. Alves, C.C. Romao, J. Organomet. Chem. 693     
    (2008) 675   
[20] T. Mosmann,  J. Immunol. Methods. 65 (1983) 55    
[21] F.M. Freimoser, C.A. Jacob, M. Aebi, U. Tuor, Appl. Environ. Microbiol. 65  
    (1999) 3727 
[22] A.S. Abu-Surrah, M. Kettunen, Curr. Med. Chem. 13 (2006) 1337   
[23] G. Zhao, H. Lin, P. Yu, H. Sun, S. Zhu, X. Su, Y. Chen, J. Inorg. Biochem. 73  
    (1999) 145 
[24] M.A. Fuertes, C. Alonso, J.M. Perez, Chem. Rev. 103 (2003) 645   
[25] Y. Jung, S.J. Lippard, Chem. Rev 107 (2007) 1387   
 
